
ISTH updates factor-concentrate guidance for perioperative bleeding
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
Updated ISTH guidance reviews current evidence and expert consensus on fibrinogen, prothrombin complex, recombinant factor VIIa, and factor XIII concentrates for acquired perioperative coagulopathy.
What NurseJet pulled from the source
The guidance addresses major surgical bleeding in cardiac, trauma, obstetric, and transplant settings. It describes acquired perioperative coagulopathy as multifactorial and updates the ISTH's 2018 document using newer clinical studies, systematic reviews, evolving practice, and expert consensus. The PubMed abstract establishes the agents and settings covered but does not provide dosing or individual recommendation strength.
Why this matters for nurses
Critical-care, emergency, perioperative, and obstetric nurses coordinate rapid assessment, specimen collection, blood-product and medication administration, warming, monitoring, and escalation during major bleeding. The update provides a current evidence framework for multidisciplinary protocols without replacing local algorithms or prescriber-directed selection.
Bedside takeaway
Use the current multidisciplinary bleeding protocol and verify every factor concentrate rather than treating the agents as interchangeable.
How This Applies in Practice
Use this when: Supporting a patient with major perioperative, traumatic, obstetric, or transplant-related bleeding and an activated coagulation-management pathway.
On your shift
- Communicate the bleeding source, estimated loss, temperature, hemodynamic trend, transfusions, medications, and ordered coagulation results to the response team.
- Verify the prescribed concentrate, indication, dose, route, compatibility, and required monitoring with the approved protocol before administration.
- Trend clinical bleeding, hemodynamics, laboratory response, and possible thrombotic or transfusion-related complications and escalate changes promptly.
Key takeaways
- The ISTH document covers factor-concentrate use for bleeding in cardiac surgery, trauma, obstetric care, and organ transplantation.
- It reviews fibrinogen concentrate, prothrombin complex concentrate, recombinant activated factor VII, and factor XIII concentrate.
- The guidance incorporates evidence published since the prior 2018 ISTH guidance and evolving bleeding-management practice.
- Its pragmatic guidance is based on the available evidence and expert consensus; the abstract does not support a single universal regimen.
Practice implications
- Activate the approved major-bleeding pathway, communicate the surgical context and evolving blood loss, obtain ordered coagulation testing promptly, and verify the exact product, dose, route, and monitoring plan before administration. Track response and complications through the local protocol.
Limitations & cautions
- The accessible PubMed abstract describes the guidance scope but does not list agent-specific indications, contraindications, doses, evidence certainty, or recommendation strength. Those details require review of the full guidance, and expert consensus contributes where evidence is limited.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
Journal of thrombosis and haemostasis : JTH (PubMed)
Journal of thrombosis and haemostasis : JTH (PubMed). Use of Factor Concentrates for the Management of Perioperative Bleeding: Guidance from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis.
https://pubmed.ncbi.nlm.nih.gov/42665231/
Professional education only


